Literature DB >> 28935344

Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Alexander David Barrow1, Marco Colonna2.   

Abstract

Natural killer (NK) cells are cytotoxic and cytokine-secreting cells that can mediate potent anti-tumour activity. Accumulating evidence indicates that NK cell functions are severely compromised within the confines of the tumour microenvironment thus impairing the efficacy and development of NK cell-based therapies. Here we review the various cellular and molecular pathways that tumours have supplanted to evade NK cell surveillance. We highlight novel strategies designed to alleviate or circumvent the immunosuppressive conditions of the tumour microenvironment in order to emancipate NK cell function and stifle the inexorable growth and metastasis of malignant cells.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Checkpoint blockade; Immunosuppression; Immunotherapy; Inhibitory receptors; Natural Killer cell; Tumour microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28935344      PMCID: PMC5659759          DOI: 10.1016/j.smim.2017.09.001

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  105 in total

1.  Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.

Authors:  Arabella Young; Deepak Mittal; Kimberley Stannard; Michelle Yong; Michele Wl Teng; Bertrand Allard; John Stagg; Mark J Smyth
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

2.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

3.  TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Authors:  Annamaria Biroccio; Julien Cherfils-Vicini; Adeline Augereau; Sébastien Pinte; Serge Bauwens; Jing Ye; Thomas Simonet; Béatrice Horard; Karine Jamet; Ludovic Cervera; Aaron Mendez-Bermudez; Delphine Poncet; Renée Grataroli; Claire T'kint de Rodenbeeke; Erica Salvati; Angela Rizzo; Pasquale Zizza; Michelle Ricoul; Céline Cognet; Thomas Kuilman; Helene Duret; Florian Lépinasse; Jacqueline Marvel; Els Verhoeyen; François-Loïc Cosset; Daniel Peeper; Mark J Smyth; Arturo Londoño-Vallejo; Laure Sabatier; Vincent Picco; Gilles Pages; Jean-Yves Scoazec; Antonella Stoppacciaro; Carlo Leonetti; Eric Vivier; Eric Gilson
Journal:  Nat Cell Biol       Date:  2013-06-23       Impact factor: 28.824

4.  Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool.

Authors:  Oren Hershkovitz; Mostafa Jarahian; Alon Zilka; Ahuva Bar-Ilan; Guy Landau; Sergey Jivov; Yoram Tekoah; Rachel Glicklis; John T Gallagher; Sabrina C Hoffmann; Hagit Zer; Ofer Mandelboim; Carsten Watzl; Frank Momburg; Angel Porgador
Journal:  Glycobiology       Date:  2007-11-15       Impact factor: 4.313

Review 5.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

6.  Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.

Authors:  Todd V Brennan; Liwen Lin; Joshua D Brandstadter; Victoria R Rendell; Keith Dredge; Xiaopei Huang; Yiping Yang
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

7.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors:  Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2007-09-28       Impact factor: 22.113

8.  Complement factor P is a ligand for the natural killer cell-activating receptor NKp46.

Authors:  Laurent Gauthier; Myriam Baratin; Sophie Guia; Aurore Fenis; Emilie Narni-Mancinelli; Ala-Eddine Deghmane; Benjamin Rossi; Patrick Fourquet; Bertrand Escalière; Yann M Kerdiles; Sophie Ugolini; Muhamed-Kheir Taha; Eric Vivier
Journal:  Sci Immunol       Date:  2017-04-28

9.  Survival in acute myeloid leukemia is associated with NKp44 splice variants.

Authors:  Avishai Shemesh; Michael Brusilovsky; Uzi Hadad; Omri Teltsh; Avishay Edri; Eitan Rubin; Kerry S Campbell; Benyamin Rosental; Angel Porgador
Journal:  Oncotarget       Date:  2016-05-31

10.  Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.

Authors:  Jason E Hudak; Stephen M Canham; Carolyn R Bertozzi
Journal:  Nat Chem Biol       Date:  2013-11-24       Impact factor: 15.040

View more
  14 in total

1.  Topography of cancer-associated immune cells in human solid tumors.

Authors:  Jakob Nikolas Kather; Meggy Suarez-Carmona; Pornpimol Charoentong; Cleo-Aron Weis; Daniela Hirsch; Peter Bankhead; Marcel Horning; Dyke Ferber; Ivan Kel; Esther Herpel; Sarah Schott; Inka Zörnig; Jochen Utikal; Alexander Marx; Timo Gaiser; Herrmann Brenner; Jenny Chang-Claude; Michael Hoffmeister; Dirk Jäger; Niels Halama
Journal:  Elife       Date:  2018-09-04       Impact factor: 8.140

Review 2.  The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer.

Authors:  Alexander James Sedgwick; Nazanin Ghazanfari; Patrick Constantinescu; Theo Mantamadiotis; Alexander David Barrow
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

Review 3.  Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.

Authors:  Francesca Romana Mariotti; Linda Quatrini; Enrico Munari; Paola Vacca; Lorenzo Moretta
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

Review 4.  The Natural Cytotoxicity Receptors in Health and Disease.

Authors:  Alexander David Barrow; Claudia Jane Martin; Marco Colonna
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

Review 5.  An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.

Authors:  Massimo Vitale; Claudia Cantoni; Mariella Della Chiesa; Guido Ferlazzo; Simona Carlomagno; Daniela Pende; Michela Falco; Annamaria Pessino; Letizia Muccio; Andrea De Maria; Emanuela Marcenaro; Lorenzo Moretta; Simona Sivori
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 6.  Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.

Authors:  Massimo Giuliani; Alessandro Poggi
Journal:  Cells       Date:  2020-06-29       Impact factor: 6.600

7.  Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.

Authors:  Ziqing Chen; Ying Yang; Shi Y Neo; Hao Shi; Yi Chen; Arnika K Wagner; Karin Larsson; Le Tong; Per-Johan Jakobsson; Evren Alici; Jing Wu; Yihai Cao; Kai Wang; Lisa L Liu; Yumeng Mao; Dhifaf Sarhan; Andreas Lundqvist
Journal:  EMBO Rep       Date:  2021-01-22       Impact factor: 8.807

Review 8.  Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?

Authors:  Jennifer Wu
Journal:  Crit Rev Immunol       Date:  2021       Impact factor: 2.214

Review 9.  Natural killer cells in pancreatic cancer stroma.

Authors:  Rachel Elizabeth Ann Fincham; Francesca Romana Delvecchio; Michelle R Goulart; Joe Poe Sheng Yeong; Hemant M Kocher
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

10.  High GJB2 mRNA expression and its prognostic significance in lung adenocarcinoma: a study based on the TCGA database.

Authors:  Yun Tang; You-Jing Zhang; Zeng-Hong Wu
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.